Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program
详细信息 查看全文
- 作者：Selim Corbacioglu1 ; selim.corbacioglu@ukr.de" class="auth_mail" title="E-mail the corresponding author ; Enric Carreras2 ; Mohamad Mohty3 ; 4 ; 5 ; Antonio Pagliuca6 ; Jaap Jan Boelens7 ; 8 ; Gandhi Damaj9 ; Massimo Iacobelli10 ; &dagger ; ; Dietger Niederwieser11 ; Eduardo Olavarrí ; a12 ; Felipe Suarez13 ; Tapani Ruutu14 ; Leo Verdonck15 ; Robin Hume16 ; Bijan Nejadnik16 ; &Dagger ; ; Chinglin Lai16 ; &Dagger ; ; Giorgia Finetto17 ; § ; ; Paul Richardson18
- 关键词：Defibrotide ; Compassionate-use program ; Stem cell transplantation ; Hepatic veno-occlusive disease ; Sinusoidal obstruction syndrome
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：22
- 期：10
- 页码：1874-1882
- 全文大小：486 K
文摘
- •
Veno-occlusive disease/sinusoidal obstruction syndrome can be severe
- •
Severe veno-occlusive disease/sinusoidal obstruction syndrome can develop unpredictably and can be fatal
- •
Defibrotide has demonstrated efficacy and safety in treatment of veno-occlusive disease/sinusoidal obstruction syndrome
- •
Safety and efficacy were consistent with prior studies of defibrotide in veno-occlusive disease/sinusoidal obstruction syndrome
- •
Subgroup results lend support to the 25 mg/kg/day recommended dose for defibrotide